Abstract: AIM: To provide clinical drug reference by systematically evaluating relevant literature of cilostazol, clopidogrel and aspirin triple anti-platelet medication in patients who underwent coronary stenting. METHODS: Five randomized controlled trials concerning the effect of cilostazol, clopidogrel and aspirin on platelet aggregation and coronary stent restenosis rate were retrieved and RevMan v.5.0 was used for the meta-analysis of platelet aggregation inhibition rate, minimal luminal diameter (MLD), late lumen loss, and restenosis rate for the evaluation of indicators. RESULTS: Except for the inhibition rate of ADP-induced platelet aggregation, significant differences were found between the experimental and control groups in MLD, late lumen loss, and restenosis rate for the evaluation of indicators. CONCLUSION: Compared with dual anti-platelet regime with aspirin plus clopidogrel, triple anti-platelet therapy with aspirin and clopidogrel combined with cilostazol is more efficient in suppressing restenosis after coronary stent implantation. Large-scale clinical trials are needed to confirm the efficacy and safety of the triple anti-platelet regimen.